

Industry Spotlight

New Method May Lead to Better CKD Testing

Researchers at Translational Genomics Research Institute (TGen) of Phoenix, AZ, have developed a promising way to isolate exosomes—tiny cell components that contain genetic and other useful information—from urine.

Exosomes are being widely studied because they may contain biomarker clues that could serve as the basis of new early diagnostic tests for chronic kidney disease (CKD). Found in urine, these cellular components may provide information about the very earliest changes in kidney function.

“Our method of extracting exosomes from urine is simple, fast, and easily adapted to clinical research, so we can ultimately help physicians provide better therapies for their patients,” said Johanna DiStefano, PhD, director of TGen’s Diabetes, Cardiovascular and Metabolic Diseases Division, and senior author of a report on the research that appeared in the July issue of *Kidney International*.

The plasma membrane in mammalian cells can fold into tiny containers called endosomes. Sometimes the membranes of some of the endosomes can in turn be internalized into even smaller vesicles, called multivesicular bodies. These become exosomes when the multivesicular bodies again merge, become part of the cell membrane, and break open to release their contents outside of the cell.

Exosome evaluations in urine samples would be useful in comparison to conventional kidney tissue biopsies, the group noted. “Unlike a kidney biopsy—an invasive and expensive procedure that provides only a small sample from one of two kidneys—urinary exosomes provide a full representation of the entire urinary system,” said Lucrecia Alvarez, PhD, the study’s lead author.

MicroRNAs (miRNAs) are important regulators of gene expression and have been linked with renal development and disease. Last year, other researchers found that in patients with severe, chronic renal failure, circulating levels of total and specific miRNAs were reduced in comparison with mild renal impairment or normal renal function. A report in *Nephrology Dialysis Transplantation* found a strong correlation exists between detected circulating miRNAs and eGFR.

In the current study, TGen researchers looked at six different methods, and found the best method for isolating exosomes was a modified protocol of an available exosome precipitation reagent called ExoQuick-TC. That reagent alone didn’t yield high quantities or pure preparations of cell proteins and RNA, which would harbor biological clues. The TGen modification of the protocol led to the highest yields of miRNA and mRNA, which can subsequently be used in genetic profiling experiments, the study showed.

Currently, CKD is typically diagnosed by detecting increased levels of urinary

albumin (a protein that is filtered out of urine in healthy kidneys) or of serum creatinine (a breakdown product of creatine, which is part of muscle).

The new TGen method has “strong potential for identifying and characterizing exosomal biomarkers from urine,” with implications for diagnosis and treatment of chronic kidney disorders, Alvarez said. ●

Amgen Acquires KAI Pharmaceuticals

Amgen Inc. recently completed its acquisition of KAI Pharmaceuticals for \$315 million. Initially agreed to on April 10, Amgen said the move was spurred by the “compelling” phase 2A trial results of KAI-4169, KAI’s compound to treat hyperthyroidism. The deal calls for Amgen to make a loan to KAI so it can plan late-stage trials of the drug.

KAI-4169 drew attention at ASN Kidney Week in Philadelphia last November when it was reported that the drug had reduced parathyroid hormone by 33 percent in patients taking a 5-mg dose and by 49 percent in those taking a 10-mg dose. It is an experimental intravenous treatment for secondary hyperparathyroidism in patients

For renal transplant patients

myfortic®: Consistent From Refill to Refill to Refill

Mycophenolate mofetil



Multiple companies offer a generic version of CellCept

- Currently, 11 different MMF tablets (500 mg) and 10 different MMF capsules (250 mg) are available^{1,*}

myfortic



Produced only by Novartis:
1 manufacturer in 1 facility

Patent protected, nonsubstitutable



myfortic and CellCept or MMF should not be used interchangeably without physician supervision because the rate of absorption following the administration of these products is not equivalent.

Demonstrated efficacy and safety in *de novo* and maintenance renal transplant patients³⁻⁵

More than 81% of myfortic prescriptions^{†,‡} had a \$0 co-pay with the Novartis Monthly Co-pay Card for eligible patients

Consistency also comes with savings:

Start your new myfortic patients with a 30-day free trial[§] by visiting www.myfortic.com or by calling the Novartis Transplant Reimbursement Access Point at 1-877-952-1000.

MMF, mycophenolate mofetil.

CELLCEPT is a registered trademark of Hoffmann-La Roche Inc.

*As of January 13, 2012.

†Based on data from the myfortic Co-pay Savings Program. Program is available to eligible patients taking myfortic and is subject to change without notice. Not valid for patients whose prescriptions are paid for by Medicare, Medicaid, or any other federally subsidized health care program, or for Massachusetts residents.

‡Initial prescription or refills based on 1-year transaction data (2011) for cash payment and insured patients combined.

§Product coverage and program subject to change without notice.

Indication:

myfortic® (mycophenolic acid) delayed-release tablet is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

Important Safety Information:

WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES, AND SERIOUS INFECTIONS

- Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning
- Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma and other neoplasms. Only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe myfortic® (mycophenolic acid) delayed-release tablet. Patients receiving myfortic should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient

- myfortic is contraindicated in patients with hypersensitivity to mycophenolate sodium, mycophenolic acid (MPA), mycophenolate mofetil (MMF), or to any of its excipients
- **Embryofetal Toxicity:** myfortic can cause fetal harm when administered to a pregnant female. Use of myfortic during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations

Please see additional Important Safety Information and Brief Summary of Prescribing Information, including **Boxed WARNINGS**, on adjacent pages.